The University of Chicago Header Logo

Connection

Everett Vokes to Humans

Back to Details
This is a "connection" page, showing publications Everett Vokes has written about Humans.
Everett Vokes
Connection Strength
2.492
Humans
  1. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul; 21(16):2007-2016.
    View in: PubMed
    Score: 0.030
  2. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
    View in: PubMed
    Score: 0.030
  3. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
    View in: PubMed
    Score: 0.028
  4. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
    View in: PubMed
    Score: 0.027
  5. Epstein-Barr Virus DNA Screening in Asymptomatic People without Known Nasopharyngeal Cancer. NEJM Evid. 2023 07; 2(7):EVIDe2300077.
    View in: PubMed
    Score: 0.026
  6. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096.
    View in: PubMed
    Score: 0.026
  7. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
    View in: PubMed
    Score: 0.026
  8. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 02 09; 388(6):489-498.
    View in: PubMed
    Score: 0.025
  9. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 05 01; 41(13):2394-2402.
    View in: PubMed
    Score: 0.025
  10. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.025
  11. 2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. J Clin Oncol. 2022 09 01; 40(25):2859-2862.
    View in: PubMed
    Score: 0.024
  12. A Global Approach to Cancer Equity in the Hispanic/Latinx Population. JCO Oncol Pract. 2022 05; 18(5):371-373.
    View in: PubMed
    Score: 0.024
  13. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.024
  14. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.023
  15. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
    View in: PubMed
    Score: 0.023
  16. Beyond PACIFIC: Uncharted Waters. J Thorac Oncol. 2021 05; 16(5):715-718.
    View in: PubMed
    Score: 0.022
  17. Is This the Dawn of Precision Oncology in Head and Neck Cancer? J Clin Oncol. 2021 06 10; 39(17):1839-1841.
    View in: PubMed
    Score: 0.022
  18. Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. Lung Cancer. 2021 06; 156:68-71.
    View in: PubMed
    Score: 0.022
  19. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021 03; 114:105171.
    View in: PubMed
    Score: 0.022
  20. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncologist. 2021 01; 26(1):40-48.
    View in: PubMed
    Score: 0.022
  21. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
    View in: PubMed
    Score: 0.021
  22. Prolonging Life, but at What Price? JAMA Otolaryngol Head Neck Surg. 2019 12 01; 145(12):1103-1104.
    View in: PubMed
    Score: 0.020
  23. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814.
    View in: PubMed
    Score: 0.020
  24. Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy. Chin Clin Oncol. 2019 Oct; 8(S1):S24.
    View in: PubMed
    Score: 0.020
  25. Palbociclib: a new partner for cetuximab? Lancet Oncol. 2019 09; 20(9):1195-1196.
    View in: PubMed
    Score: 0.020
  26. Management of Early Head and Neck Cancer in Elderly Patients. J Oncol Pract. 2018 09; 14(9):541-546.
    View in: PubMed
    Score: 0.019
  27. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1183-1188.
    View in: PubMed
    Score: 0.018
  28. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965.
    View in: PubMed
    Score: 0.018
  29. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.018
  30. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol. 2017 12; 18(12):1555-1556.
    View in: PubMed
    Score: 0.018
  31. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 05; 12(5):843-849.
    View in: PubMed
    Score: 0.017
  32. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
    View in: PubMed
    Score: 0.016
  33. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.016
  34. HPV-Associated Head and Neck Cancer. J Natl Cancer Inst. 2015 Dec; 107(12):djv344.
    View in: PubMed
    Score: 0.015
  35. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20; 33(15):1660-5.
    View in: PubMed
    Score: 0.015
  36. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
    View in: PubMed
    Score: 0.015
  37. EGFR-based bioradiotherapy in SCCHN. Lancet Oncol. 2015 Feb; 16(2):129-30.
    View in: PubMed
    Score: 0.015
  38. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.014
  39. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
    View in: PubMed
    Score: 0.014
  40. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
    View in: PubMed
    Score: 0.014
  41. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.014
  42. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Lung Cancer. 2013 Dec; 82(3):436-40.
    View in: PubMed
    Score: 0.013
  43. EGFR-directed treatments in SCCHN. Lancet Oncol. 2013 Jul; 14(8):672-3.
    View in: PubMed
    Score: 0.013
  44. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1029-38.
    View in: PubMed
    Score: 0.013
  45. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3.
    View in: PubMed
    Score: 0.013
  46. Competing roads to larynx preservation. J Clin Oncol. 2013 Mar 01; 31(7):833-5.
    View in: PubMed
    Score: 0.013
  47. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J Thorac Oncol. 2013 Jan; 8(1):102-8.
    View in: PubMed
    Score: 0.013
  48. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.013
  49. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.012
  50. Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Jun 01; 30(16):2019-20; author reply 2020.
    View in: PubMed
    Score: 0.012
  51. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9.
    View in: PubMed
    Score: 0.012
  52. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.012
  53. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7.
    View in: PubMed
    Score: 0.012
  54. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20; 29(33):4436-41.
    View in: PubMed
    Score: 0.012
  55. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011 Aug 10; 29(23):3120-5.
    View in: PubMed
    Score: 0.011
  56. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
    View in: PubMed
    Score: 0.011
  57. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
    View in: PubMed
    Score: 0.011
  58. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4.
    View in: PubMed
    Score: 0.011
  59. Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8.
    View in: PubMed
    Score: 0.011
  60. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
    View in: PubMed
    Score: 0.011
  61. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
    View in: PubMed
    Score: 0.011
  62. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
    View in: PubMed
    Score: 0.011
  63. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.011
  64. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
    View in: PubMed
    Score: 0.010
  65. Induction chemotherapy for head and neck cancer: recent data. Oncologist. 2010; 15 Suppl 3:3-7.
    View in: PubMed
    Score: 0.010
  66. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov; 14(11):1116-30.
    View in: PubMed
    Score: 0.010
  67. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol. 2009 Sep 20; 27(27):4487-91.
    View in: PubMed
    Score: 0.010
  68. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60.
    View in: PubMed
    Score: 0.010
  69. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009 May; 10(3):193-8.
    View in: PubMed
    Score: 0.010
  70. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71.
    View in: PubMed
    Score: 0.010
  71. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.010
  72. Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009 Jan; 19(1):11-6.
    View in: PubMed
    Score: 0.010
  73. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6.
    View in: PubMed
    Score: 0.009
  74. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.009
  75. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008 Aug; 3(8):917-28.
    View in: PubMed
    Score: 0.009
  76. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7.
    View in: PubMed
    Score: 0.009
  77. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol. 2008 Jun; 35(3):251-61.
    View in: PubMed
    Score: 0.009
  78. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63.
    View in: PubMed
    Score: 0.009
  79. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.009
  80. Combining radiotherapy with systemic therapies. Clin Adv Hematol Oncol. 2008 Mar; 6(3):167-9.
    View in: PubMed
    Score: 0.009
  81. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
    View in: PubMed
    Score: 0.009
  82. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008 Jan-Feb; 58(1):32-53.
    View in: PubMed
    Score: 0.009
  83. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007 Sep 10; 25(26):4118-26.
    View in: PubMed
    Score: 0.009
  84. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
    View in: PubMed
    Score: 0.009
  85. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 01; 25(13):1698-704.
    View in: PubMed
    Score: 0.008
  86. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007 Mar; 4(3):156-71.
    View in: PubMed
    Score: 0.008
  87. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100.
    View in: PubMed
    Score: 0.008
  88. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
    View in: PubMed
    Score: 0.008
  89. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.008
  90. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol. 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2.
    View in: PubMed
    Score: 0.008
  91. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.008
  92. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
    View in: PubMed
    Score: 0.008
  93. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
    View in: PubMed
    Score: 0.008
  94. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park). 2006 Apr; 20(5 Suppl 2):15-25.
    View in: PubMed
    Score: 0.008
  95. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9.
    View in: PubMed
    Score: 0.008
  96. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):245-51.
    View in: PubMed
    Score: 0.008
  97. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
    View in: PubMed
    Score: 0.008
  98. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
    View in: PubMed
    Score: 0.008
  99. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S98-104.
    View in: PubMed
    Score: 0.008
  100. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.008
  101. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5.
    View in: PubMed
    Score: 0.008
  102. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93.
    View in: PubMed
    Score: 0.008
  103. Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer. 2005 Oct; 50 Suppl 1:S20-2.
    View in: PubMed
    Score: 0.008
  104. Optimal therapy for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01; 23(25):5853-5.
    View in: PubMed
    Score: 0.008
  105. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005 Aug; 28(4):340-4.
    View in: PubMed
    Score: 0.008
  106. Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer. Clin Cancer Res. 2025 Aug 01; 31(15):3150-3159.
    View in: PubMed
    Score: 0.008
  107. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5045s-5050s.
    View in: PubMed
    Score: 0.007
  108. Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA. Oral Oncol. 2025 Aug; 167:107445.
    View in: PubMed
    Score: 0.007
  109. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Jul; 643(8072):810-819.
    View in: PubMed
    Score: 0.007
  110. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005 Oct; 56(4):421-6.
    View in: PubMed
    Score: 0.007
  111. Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncol. 2025 Apr; 163:107207.
    View in: PubMed
    Score: 0.007
  112. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
    View in: PubMed
    Score: 0.007
  113. PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
    View in: PubMed
    Score: 0.007
  114. Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol. 2005; 16 Suppl 6:vi25-vi30.
    View in: PubMed
    Score: 0.007
  115. Update in head and neck oncology. Semin Oncol. 2004 Dec; 31(6):717.
    View in: PubMed
    Score: 0.007
  116. Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93.
    View in: PubMed
    Score: 0.007
  117. Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 2025 Jan 01; 131(1):e35663.
    View in: PubMed
    Score: 0.007
  118. Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538. JAMA Netw Open. 2024 10 01; 7(10):e2440673.
    View in: PubMed
    Score: 0.007
  119. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 2024 09 01; 10(9):1212-1219.
    View in: PubMed
    Score: 0.007
  120. Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 09 01; 10(9):1179-1186.
    View in: PubMed
    Score: 0.007
  121. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.007
  122. 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.
    View in: PubMed
    Score: 0.007
  123. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
    View in: PubMed
    Score: 0.007
  124. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
    View in: PubMed
    Score: 0.007
  125. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.007
  126. Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit. JCO Glob Oncol. 2024 05; 10:e2300256.
    View in: PubMed
    Score: 0.007
  127. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
    View in: PubMed
    Score: 0.007
  128. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.007
  129. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15; 22(6):1110-7.
    View in: PubMed
    Score: 0.007
  130. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
    View in: PubMed
    Score: 0.007
  131. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024 Jul; 19(7):1108-1116.
    View in: PubMed
    Score: 0.007
  132. Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck. 2004 Feb; 26(2):163-70.
    View in: PubMed
    Score: 0.007
  133. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90.
    View in: PubMed
    Score: 0.007
  134. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.007
  135. Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer. 2003 Dec; 42 Suppl 1:S65-9.
    View in: PubMed
    Score: 0.007
  136. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.007
  137. Therapeutic options for laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2087-9.
    View in: PubMed
    Score: 0.007
  138. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52.
    View in: PubMed
    Score: 0.007
  139. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
    Score: 0.007
  140. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023 12; 18(12):1731-1742.
    View in: PubMed
    Score: 0.007
  141. Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer. 2003 Aug; 41 Suppl 1:S115-21.
    View in: PubMed
    Score: 0.007
  142. Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies. JAMA Netw Open. 2023 06 01; 6(6):e2319055.
    View in: PubMed
    Score: 0.006
  143. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
    View in: PubMed
    Score: 0.006
  144. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 May 01; 21(9):1760-6.
    View in: PubMed
    Score: 0.006
  145. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.006
  146. Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer. Future Oncol. 2023 Mar; 19(8):549-557.
    View in: PubMed
    Score: 0.006
  147. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6.
    View in: PubMed
    Score: 0.006
  148. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
    View in: PubMed
    Score: 0.006
  149. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.006
  150. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003; 8(4):350-60.
    View in: PubMed
    Score: 0.006
  151. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.006
  152. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
    View in: PubMed
    Score: 0.006
  153. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35.
    View in: PubMed
    Score: 0.006
  154. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.006
  155. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 11 02; 13(1):6572.
    View in: PubMed
    Score: 0.006
  156. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
    View in: PubMed
    Score: 0.006
  157. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002 Oct 15; 20(20):4191-8.
    View in: PubMed
    Score: 0.006
  158. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
    View in: PubMed
    Score: 0.006
  159. An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck. Cancer. 2002 Jul 01; 95(1):98-104.
    View in: PubMed
    Score: 0.006
  160. Curative treatment for advanced head and neck cancer in the community: has the time come? Cancer J. 2002 Jul-Aug; 8(4):298-300.
    View in: PubMed
    Score: 0.006
  161. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985.
    View in: PubMed
    Score: 0.006
  162. Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
    View in: PubMed
    Score: 0.006
  163. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198.
    View in: PubMed
    Score: 0.006
  164. Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61.
    View in: PubMed
    Score: 0.006
  165. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.006
  166. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.006
  167. Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. Lung Cancer. 2001 Sep; 33 Suppl 1:S85-9.
    View in: PubMed
    Score: 0.006
  168. Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644.
    View in: PubMed
    Score: 0.006
  169. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
    View in: PubMed
    Score: 0.006
  170. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.006
  171. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 06 15; 6(60).
    View in: PubMed
    Score: 0.006
  172. Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Netw Open. 2021 05 03; 4(5):e2110438.
    View in: PubMed
    Score: 0.006
  173. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021 05; 22(5):727-736.
    View in: PubMed
    Score: 0.006
  174. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.006
  175. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.006
  176. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist. 2001; 6 Suppl 1:25-7.
    View in: PubMed
    Score: 0.005
  177. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 2001; 19(4):329-33.
    View in: PubMed
    Score: 0.005
  178. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601.
    View in: PubMed
    Score: 0.005
  179. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. Clin Lung Cancer. 2020 11; 21(6):553-561.e1.
    View in: PubMed
    Score: 0.005
  180. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. J Thorac Oncol. 2020 08; 15(8):1306-1316.
    View in: PubMed
    Score: 0.005
  181. Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):662-671.
    View in: PubMed
    Score: 0.005
  182. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.005
  183. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
    View in: PubMed
    Score: 0.005
  184. A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019 11; 41(11):3842-3849.
    View in: PubMed
    Score: 0.005
  185. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Curr Med Res Opin. 2019 10; 35(10):1761-1767.
    View in: PubMed
    Score: 0.005
  186. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
    View in: PubMed
    Score: 0.005
  187. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
    View in: PubMed
    Score: 0.005
  188. Clinical prognostic model for older patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019 07; 10(4):555-559.
    View in: PubMed
    Score: 0.005
  189. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 12; 6(12):915-924.
    View in: PubMed
    Score: 0.005
  190. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019 02 01; 125(3):382-390.
    View in: PubMed
    Score: 0.005
  191. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 02; 14(2):298-303.
    View in: PubMed
    Score: 0.005
  192. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082.
    View in: PubMed
    Score: 0.005
  193. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. J Thorac Oncol. 2018 08; 13(8):1171-1182.
    View in: PubMed
    Score: 0.005
  194. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 06; 81:45-51.
    View in: PubMed
    Score: 0.005
  195. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clin Lung Cancer. 2018 09; 19(5):377-386.
    View in: PubMed
    Score: 0.005
  196. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
    View in: PubMed
    Score: 0.005
  197. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018 05 15; 124(10):2174-2183.
    View in: PubMed
    Score: 0.005
  198. Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population. Head Neck. 2018 04; 40(4):784-792.
    View in: PubMed
    Score: 0.004
  199. Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018 05; 19(3):230-238.e2.
    View in: PubMed
    Score: 0.004
  200. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933.
    View in: PubMed
    Score: 0.004
  201. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
    View in: PubMed
    Score: 0.004
  202. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.
    View in: PubMed
    Score: 0.004
  203. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
    View in: PubMed
    Score: 0.004
  204. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192.
    View in: PubMed
    Score: 0.004
  205. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907.
    View in: PubMed
    Score: 0.004
  206. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.004
  207. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
    View in: PubMed
    Score: 0.004
  208. AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck. 2017 02; 39(2):201-205.
    View in: PubMed
    Score: 0.004
  209. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
    View in: PubMed
    Score: 0.004
  210. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207.
    View in: PubMed
    Score: 0.004
  211. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 01; 18(1):5-12.
    View in: PubMed
    Score: 0.004
  212. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.004
  213. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62.
    View in: PubMed
    Score: 0.004
  214. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). J Thorac Oncol. 2016 Mar; 11(3):361-9.
    View in: PubMed
    Score: 0.004
  215. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44.
    View in: PubMed
    Score: 0.004
  216. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22; 373(17):1627-39.
    View in: PubMed
    Score: 0.004
  217. Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer. 2015 Nov; 90(2):281-7.
    View in: PubMed
    Score: 0.004
  218. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75.
    View in: PubMed
    Score: 0.004
  219. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106.
    View in: PubMed
    Score: 0.004
  220. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
    View in: PubMed
    Score: 0.004
  221. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.004
  222. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1222-8.
    View in: PubMed
    Score: 0.004
  223. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74.
    View in: PubMed
    Score: 0.004
  224. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24.
    View in: PubMed
    Score: 0.004
  225. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol. 2015 Jan; 10(1):143-7.
    View in: PubMed
    Score: 0.004
  226. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
    View in: PubMed
    Score: 0.004
  227. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8.
    View in: PubMed
    Score: 0.004
  228. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.004
  229. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol. 2014 Sep; 50(9):825-31.
    View in: PubMed
    Score: 0.004
  230. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.003
  231. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21.
    View in: PubMed
    Score: 0.003
  232. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
    View in: PubMed
    Score: 0.003
  233. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.003
  234. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
    View in: PubMed
    Score: 0.003
  235. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013 Aug; 8(8):1043-9.
    View in: PubMed
    Score: 0.003
  236. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.003
  237. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
    View in: PubMed
    Score: 0.003
  238. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33.
    View in: PubMed
    Score: 0.003
  239. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91.
    View in: PubMed
    Score: 0.003
  240. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33.
    View in: PubMed
    Score: 0.003
  241. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
    View in: PubMed
    Score: 0.003
  242. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.003
  243. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
    View in: PubMed
    Score: 0.003
  244. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
    View in: PubMed
    Score: 0.003
  245. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
    View in: PubMed
    Score: 0.003
  246. Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
    View in: PubMed
    Score: 0.003
  247. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012 Jun 10; 30(17):2063-9.
    View in: PubMed
    Score: 0.003
  248. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
    View in: PubMed
    Score: 0.003
  249. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr; 7(4):649-54.
    View in: PubMed
    Score: 0.003
  250. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
    View in: PubMed
    Score: 0.003
  251. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8.
    View in: PubMed
    Score: 0.003
  252. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.003
  253. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.003
  254. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
    View in: PubMed
    Score: 0.003
  255. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011 Nov; 6(11):1902-6.
    View in: PubMed
    Score: 0.003
  256. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.003
  257. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5.
    View in: PubMed
    Score: 0.003
  258. Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61.
    View in: PubMed
    Score: 0.003
  259. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
    View in: PubMed
    Score: 0.003
  260. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
    View in: PubMed
    Score: 0.003
  261. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
    View in: PubMed
    Score: 0.003
  262. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther. 2011 Jul; 10(7):1185-93.
    View in: PubMed
    Score: 0.003
  263. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.003
  264. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer. 2011 Nov; 74(2):258-63.
    View in: PubMed
    Score: 0.003
  265. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e269-74.
    View in: PubMed
    Score: 0.003
  266. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
    View in: PubMed
    Score: 0.003
  267. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
    View in: PubMed
    Score: 0.003
  268. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.003
  269. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34.
    View in: PubMed
    Score: 0.003
  270. Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck. 2010 Nov; 32(11):1519-27.
    View in: PubMed
    Score: 0.003
  271. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
    View in: PubMed
    Score: 0.003
  272. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010 Oct; 5(10):1644-8.
    View in: PubMed
    Score: 0.003
  273. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
    View in: PubMed
    Score: 0.003
  274. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.003
  275. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep; 5(9):1382-90.
    View in: PubMed
    Score: 0.003
  276. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84.
    View in: PubMed
    Score: 0.003
  277. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol. 2010 Jun; 5(6):810-7.
    View in: PubMed
    Score: 0.003
  278. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11.
    View in: PubMed
    Score: 0.003
  279. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
    View in: PubMed
    Score: 0.003
  280. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010 Mar; 5(3):380-4.
    View in: PubMed
    Score: 0.003
  281. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40.
    View in: PubMed
    Score: 0.003
  282. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One. 2010 Jan 29; 5(1):e8972.
    View in: PubMed
    Score: 0.003
  283. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010 Jan 10; 28(2):202-6.
    View in: PubMed
    Score: 0.003
  284. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62.
    View in: PubMed
    Score: 0.003
  285. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010 Jan 10; 28(2):215-21.
    View in: PubMed
    Score: 0.003
  286. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.003
  287. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404.
    View in: PubMed
    Score: 0.003
  288. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Nov; 135(11):1133-6.
    View in: PubMed
    Score: 0.003
  289. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1117-25.
    View in: PubMed
    Score: 0.003
  290. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.003
  291. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80.
    View in: PubMed
    Score: 0.003
  292. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30.
    View in: PubMed
    Score: 0.003
  293. The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2010 Dec; 28(6):854-8.
    View in: PubMed
    Score: 0.002
  294. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
    View in: PubMed
    Score: 0.002
  295. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.002
  296. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009 Aug 10; 27(23):3836-41.
    View in: PubMed
    Score: 0.002
  297. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22.
    View in: PubMed
    Score: 0.002
  298. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.002
  299. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J Thorac Oncol. 2009 Feb; 4(2):220-6.
    View in: PubMed
    Score: 0.002
  300. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
    View in: PubMed
    Score: 0.002
  301. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
    View in: PubMed
    Score: 0.002
  302. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov; 3(11):1301-7.
    View in: PubMed
    Score: 0.002
  303. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51.
    View in: PubMed
    Score: 0.002
  304. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
    View in: PubMed
    Score: 0.002
  305. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65.
    View in: PubMed
    Score: 0.002
  306. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
    View in: PubMed
    Score: 0.002
  307. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
    View in: PubMed
    Score: 0.002
  308. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.002
  309. MET as a target for treatment of chest tumors. Lung Cancer. 2009 Feb; 63(2):169-79.
    View in: PubMed
    Score: 0.002
  310. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
    View in: PubMed
    Score: 0.002
  311. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.
    View in: PubMed
    Score: 0.002
  312. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
    View in: PubMed
    Score: 0.002
  313. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
    View in: PubMed
    Score: 0.002
  314. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer. 2008 Oct; 62(1):92-8.
    View in: PubMed
    Score: 0.002
  315. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.002
  316. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91.
    View in: PubMed
    Score: 0.002
  317. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008 Feb 20; 26(6):848-55.
    View in: PubMed
    Score: 0.002
  318. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008 Feb; 3(2):158-62.
    View in: PubMed
    Score: 0.002
  319. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
    View in: PubMed
    Score: 0.002
  320. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
    View in: PubMed
    Score: 0.002
  321. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15.
    View in: PubMed
    Score: 0.002
  322. Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95.
    View in: PubMed
    Score: 0.002
  323. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26.
    View in: PubMed
    Score: 0.002
  324. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
    View in: PubMed
    Score: 0.002
  325. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007 Sep 01; 25(25):3978-84.
    View in: PubMed
    Score: 0.002
  326. Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. Head Neck. 2007 Jul; 29(7):632-7.
    View in: PubMed
    Score: 0.002
  327. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul; 2(7):645-51.
    View in: PubMed
    Score: 0.002
  328. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3.
    View in: PubMed
    Score: 0.002
  329. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
    View in: PubMed
    Score: 0.002
  330. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer. 2007 Jan; 8(4):268-72.
    View in: PubMed
    Score: 0.002
  331. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S1-3.
    View in: PubMed
    Score: 0.002
  332. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
    View in: PubMed
    Score: 0.002
  333. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.002
  334. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.002
  335. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
    View in: PubMed
    Score: 0.002
  336. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.002
  337. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
    View in: PubMed
    Score: 0.002
  338. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
    View in: PubMed
    Score: 0.002
  339. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006 Jan 20; 24(3):407-12.
    View in: PubMed
    Score: 0.002
  340. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
    View in: PubMed
    Score: 0.002
  341. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
    View in: PubMed
    Score: 0.002
  342. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46.
    View in: PubMed
    Score: 0.002
  343. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
    View in: PubMed
    Score: 0.002
  344. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20; 23(24):5578-87.
    View in: PubMed
    Score: 0.002
  345. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s.
    View in: PubMed
    Score: 0.002
  346. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer. 2005 Jul; 7(1):47-53.
    View in: PubMed
    Score: 0.002
  347. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 01; 23(16):3752-9.
    View in: PubMed
    Score: 0.002
  348. A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4.
    View in: PubMed
    Score: 0.002
  349. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
    View in: PubMed
    Score: 0.002
  350. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005 Jan 20; 23(3):585-90.
    View in: PubMed
    Score: 0.002
  351. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
    View in: PubMed
    Score: 0.002
  352. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15; 22(14):2918-26.
    View in: PubMed
    Score: 0.002
  353. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.002
  354. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.002
  355. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.002
  356. Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004 Feb; 31(1 Suppl 1):61-7.
    View in: PubMed
    Score: 0.002
  357. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 Jan 01; 22(1):77-85.
    View in: PubMed
    Score: 0.002
  358. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 01; 22(1):115-9.
    View in: PubMed
    Score: 0.002
  359. Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1219-30.
    View in: PubMed
    Score: 0.002
  360. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.